

Daniel A Erlanson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1824330/publications.pdf>

Version: 2024-02-01

15
papers

1,485
citations

687363

13
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

2446
citing authors

#	ARTICLE	IF	CITATIONS
1	Twenty years on: the impact of fragments on drug discovery. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 605-619.	46.4	711
2	Learning from our mistakes: The “unknown knowns”™ in fragment screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2844-2852.	2.2	136
3	Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures. <i>Cell Chemical Biology</i> , 2019, 26, 9-15.	5.2	119
4	Validity of Ligand Efficiency Metrics. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 616-618.	2.8	112
5	Discovery of <i>N</i> -(1-Acryloylazetid-3-yl)-2-(1 <i>H</i> -indol-1-yl)acetamides as Covalent Inhibitors of KRAS ^{G12C} . <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1302-1308.	2.8	66
6	Fragment-to-Lead Medicinal Chemistry Publications in 2018. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4430-4444.	6.4	61
7	Fragment-to-Lead Medicinal Chemistry Publications in 2020. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 84-99.	6.4	52
8	Fragment-to-Lead Medicinal Chemistry Publications in 2015. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 89-99.	6.4	47
9	Fragment-to-Lead Medicinal Chemistry Publications in 2017. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3857-3872.	6.4	47
10	Fragment-to-Lead Medicinal Chemistry Publications in 2016. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1774-1784.	6.4	41
11	Fragment-to-Lead Medicinal Chemistry Publications in 2019. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15494-15507.	6.4	41
12	Many small steps towards a COVID-19 drug. <i>Nature Communications</i> , 2020, 11, 5048.	12.8	18
13	Targeting mutant KRAS. <i>Current Opinion in Chemical Biology</i> , 2021, 62, 101-108.	6.1	16
14	Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2905-2913.	3.0	14
15	The future of covalent inhibition. <i>Annual Reports in Medicinal Chemistry</i> , 2021, 56, 267-284.	0.9	0